Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lorenz Bankel
Observed names:
Bankel, Lorenz,
L. Bankel
Institutions:
University of Zurich,
University Hospital Zurich
Observed institutions:
University of Zurich,
Helmholtz Munich,
ETH Zurich,
University Hospital Zurich,
Institute for Molecular Systems Biology
ORCID:
0000-0002-4650-7830
Observed ORCID:
0000-0002-4650-7830
OpenAlex ID:
A5019556912
Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN‐γ and induces NK cell‐dependent lymphoma control without other immunotherapies
2017
·
Johann Pötzl
, David Roser
, et al.
·
International Journal of Cancer
·
127
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
2020
·
S. Hiltbrunner
, C. Britschgi
, et al.
·
Annals of Oncology
·
104
PDF
A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
2019
·
A. Curioni
, C. Britschgi
, et al.
·
Annals of Oncology
·
58
18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non–Small Cell Lung Cancer
2019
·
Dilara Akhoundova
, Stefanie Hiltbrunner
, et al.
·
Clinical Nuclear Medicine
·
30
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
2023
·
Lara Planas‐Paz
, Alicia Pliego‐Mendieta
, et al.
·
EMBO Molecular Medicine
·
28
PDF
A Novel CXCL10-Based GPI-Anchored Fusion Protein as Adjuvant in NK-Based Tumor Therapy
2013
·
Niklas Muenchmeier
, Sophia Boecker
, et al.
·
PLoS ONE
·
23
PDF
Molecular and functional landscape of malignant serous effusions for precision oncology
2024
·
Rebekka Wegmann
, Lorenz Bankel
, et al.
·
Nature Communications
·
16
PDF
919O A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours
2025
·
E. Garralda
, M. Florescu
, et al.
·
Annals of Oncology
·
13
Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
2021
·
Stefanie Hiltbrunner
, Meta-Lina Spohn
, et al.
·
Cancers
·
13
PDF
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
2025
·
Willemijn Breunis
, Eva Brack
, et al.
·
Nature Communications
·
12
PDF
Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
2022
·
Alessa Fischer
, Lorenz Bankel
, et al.
·
Targeted Oncology
·
10
PDF
Outcome Analysis of Treatment Modalities for Thoracic Sarcomas
2023
·
Milos Sarvan
, Harry Etienne
, et al.
·
Cancers
·
4
Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore decision support for the Molecular Tumor Board: study protocol
2025
·
Laura Amanda Boos
, Christian Doerig
, et al.
·
BMJ Open
·
3
PDF
P3.04-22 Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
2018
·
D. Akhoundova Sanoyan
, M. Hüllner
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich
2017
·
D Akhoundova Sanoyan
, A. Siebenhüner
, et al.
·
Annals of Oncology
·
2
PDF
Dedifferentiated liposarcoma with extensive cystic change causing significant diagnostic challenges: report of two cases and review of the literature
2025
·
Viola Katharina Vetter
, Perparim Limani
, et al.
·
Diagnostic Pathology
·
1
Co-alterations associated with resistance to EGFR inhibitors in advanced EGFR-positive NSCLC: insights from the precision oncology program in two large international real-world cohorts
2026
·
LA Boos
, C. Doerig
, et al.
·
npj Precision Oncology
PDF
Doughnut-shaped bone lesions on F-FDG-PET/CT may indicate pseudoprogression under immuno(radio)therapy
2026
·
Aeschbacher, Nathan D
, Maurer, Alexander
, et al.
·
Zurich Open Repository and Archive (University of Zurich)
89P First-line chemo-immunotherapy or chemotherapy in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC): Results from a real-world analysis in Switzerland
2026
·
D. König
, T.A. Jumuga
, et al.
·
ESMO Open
99P Pharmacoscopy in soft tissue sarcoma, a single-cell ex vivo drug response testing platform
2026
·
L. Bankel
, L. Kralickova
, et al.
·
ESMO rare cancers.
Doughnut-shaped bone lesions on 18F-FDG-PET/CT may indicate pseudoprogression under immuno(radio)therapy
2026
·
Nathan D. Aeschbacher
, Alexander Maurer
, et al.
·
Annals of Nuclear Medicine
Outcomes in patients with abdominal soft tissue sarcoma: a retrospective cohort study from a single Swiss tertiary referral centre
2025
·
Johanna Nicola Werner
, Eva Breuer
, et al.
·
Swiss Medical Weekly
PDF
1965P Co-alterations driving resistance to EGFR-inhibitors (EGFRi) in advanced EGFR alteration -positive non-small cell lung cancer (EGFR+ NSCLC): Insights from the Precision Oncology Program (POP) in two international real-world cohorts
2025
·
L.A. Boos
, E. Camarillo
, et al.
·
Annals of Oncology
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
2025
·
Breunis, Willemijn
, Brack, Eva
, et al.
·
Zurich Open Repository and Archive (University of Zurich)
109P Unraveling homologous recombination deficiency and therapeutic opportunities in soft tissue and bone sarcoma
2023
·
L. Planas-Paz
, A. Pliego-Mendieta
, et al.
·
ESMO Open
Show more works
View as search
Works count:
32
Citation count:
447
H-index:
10
I10-index:
11
Year
Topic
Type